GEN Exclusives

More »

Feature Articles

More »
Aug 1, 2009 (Vol. 29, No. 14)

Bioreactor and Fermentor Market Trends

Vaccine and Biopharmaceutical Product Developments Boost Technological Innovation

  • When Smaller Is Better

    Click Image To Enlarge +
    The flower-shaped well geometry of m2p-labs’ new microbioreactor platform, Flowerplate, improves mixing and gas/liquid mass transfer, the firm reports.

    To accelerate product development, drug companies are scaling down early-stage bioprocesses to analyze and better define a range of parameters and to optimize media preparations and process conditions. Miniaturization represents a strong trend in the bioprocess industry today as companies look for innovative ways to save time, labor, and resources.

    In the area of small-scale systems, Applikon offers the MicroFlask which, company officials say, can replace orbital shake flasks for the rapid growth of microbial strains, clonal libraries, and cell lines in 24- or 96-well plates. The firm’s Micro 24 bioreactor system can perform high-throughput fermentation or cell culture in 7 mL volumes with automated, independent monitoring and control of 24 individual microreactors on one microtiter plate, explains Howard Weber, director of sales and marketing.

    Frank Kensy, managing director at m2p-labs reports strong demand from industry for miniaturized fermentation systems for clone screening and media development. The company’s BioLector system can perform 48 parallel fermentation runs at a scale of 300 to 1,500 µL, with online optical monitoring of biomass, pH, and dissolved oxygen, and the ability to detect fluorescent proteins. Being able to measure labeled biomolecules allows users to “study protein expression, characterize promoters, and study regulation by culturing different knock-outs on different substrates,” says Kensy. The benchtop system can be integrated with automated liquid-handling platforms or operated manually.

    Kensy also reports interest from the biofuels sector, which is using the BioLector to study the effects of different gases in the bioreactor chamber, to develop anaerobic processes, to screen clones for desired metabolic pathways, and to study various carbon sources to identify less costly media preparations.

    Last year, m2p released the Flowerplate microbioreactor platform for microbial cell culture, which features flower-shaped well geometry to improve mixing and gas/liquid mass transfer. The flower-shaped wells function akin to baffles in shaker flasks to disrupt the liquid stream and increase gas exchange during orbital shaking. The company reports achieving an oxygen transfer rate of 0.2 mol/L/h. The Flowerplate has 48 wells to enable parallel batch fermentation, with filling volumes of 0.3–0.5 mL.

    Dasgip introduced a new edition of control software for the Dasgip Parallel Bioreactor System, the Dasgip Control 4.0 OPC Edition, which supports the openness, productivity, and collaboration (OPC) standards for network-wide exchange of real-time data across third-party hardware platforms.

    The Dasgip control system was designed for use with glass bioreactors from 50 mL to 5 L and supporting the Thermo Scientific Hyclone S.U.B. for scale-up features mass flow controlled gas mixing, up to six liquid feeds per reactor, overpressure detection and gas flow cutoff, and integration with Hyclone temperature and agitation control.

    Falk Schneider, Ph.D., director of software engineering at Dasgip, identifies two key trends that his company’s technology is addressing: miniaturization and parallelization, to allow for scaled-down applications such as cell line screening, media optimization, and stem cell applications. The goal is to minimize process volumes, maximize the number of runs in the shortest timeframe, while still generating ample process information.

    The trend toward OPC control of the bioreactor system is driven by the FDA’s PAT initiative, and control technology, including online and at-line autosamplers, sensors, analytical devices, and integrated control software, is rapidly moving into smaller scale bioreactor systems.

    A critical gap “in many installations exists between the bioreactor data and the sampling data,” says Dr. Schneider. “We need to integrate analyzer values into process controllers in real time.” Automated process monitoring is not enough; it is important “to close the feedback loop for nutrients as an example,” he adds.

    HexaScreen Culture Technologies, a spin-off from Universitat Autònoma de Barcelona, Universitat Politècnica de Catalunya and Fundació ASCAMM, plans to introduce its first commercial bioreactor for mammalian cell culture in January. The company’s patented technology mimics traditional T-flask cultures in single-use plastic plates, each housing six individual minibioreactors, combined with noninvasive temperature, pH, and optical density control.

    “The 10 to 15 mL working volumes are small enough to save a lot of preparation time and money, but are still sufficient to collect samples for quality assurance measurements, as well as obtaining reliable data for bioprocess optimization,” says Francesc Gòdia, a founder of the company and professor of chemical engineering at the University. He describes the minibioreactors as homogeneous systems in which the internal liquid gradients and microenvironments that can form in microwell plates are avoided.

    Gòdia believes customers will find the parallel bioreactor system especially useful for replicate experiments, screening of cell lines, scale-down studies, media development, and toxicity testing. HexaScreen anticipates introducing a second model capable of performing automated fed-batch fermentation and pH control in early 2011.

  • Flu Vaccine Drives Demand

    Customer feedback to Thermo Fisher Scientific points to a “migration to modular production systems” that can be up and running quickly, moved from site to site, and give facilities multipurpose manufacturing capabilities, according to Brandon Pence, associate director of market management for Thermo Scientific cell culture and bioprocessing. Thermo’s single-use customer base is focusing on the 500–2,000 L scale, with 1,000 L being “the sweetspot right now,” says Pence.

    For pandemic flu vaccine production, for example, “we are working with companies responding to H1N1, and they are asking for process development and optimization support in single-use bioreactors” for seed train development. They want speed and ease of use “without compromising protocols. Instead of purchasing one 10,000 L system and having centralized production at one site, they want ten 1,000 L reactors that they can move to regional sites where there is need.”

    Ideally, companies would like a complete single-use process workflow, including upstream mixing of liquids, operation of the bioreactor, and harvesting of product, asserts Pence. At the core of Thermo’s disposable bioprocess product line is the stirred tank S.U.B., available in 25 L to 1,000 L working volumes, with a 2,000 vessel in development.

    The process development market, at scales of 50–250 L also remains strong, according to Pence. The company’s application center works with customers to develop and optimize processes and to customize media for a client cell lines.

    ATMI LifeSciences plans to double its global production capacity of disposable bioprocess vessels for life science applications by upgrading and modifying its manufacturing facility in Bloomington, MN, and continuing production at its plant in Brussels. ATMI’s expertise is focused on single-use mixing, storage, and bioreactor technology.

    Last year the company acquired LevTech, with its Newmix product line of scalable, single-use mixing systems for benchtop to industrial-scale applications. Subsequently, ATMI granted exclusive distribution rights to the LevTech mixing technology to Sartorius Stedim Biotech for use in its disposable bag mixing systems.

    Last December, ATMI purchased assets related to the Nucleo™ single-use bioreactor and Jet-Drive™ disposable mixing system from Artelis. Artelis and ATMI, in partnership with Pierre Guerin Technologies, jointly developed the Nucleo™ line of disposable bioreactors.

    “Artelis is focused on process intensification,” says Nicolas Havelange, business development director. He defines process intensification as scaled-down manufacturing with increased cell density and fewer unit operations. The company is developing a perfusion-based bioreactor called the iCELLis™, in which either adherent or suspension cells can be cultivated on a matrix that allows them to grow to densities of 108 up to 2x108 cells/mL.

    Havelange anticipates particular interest from the viral vaccine and cell therapy markets and reports that Artelis has a contract with GlaxoSmithKline Biologicals for vaccine production. iCELLis single-use vessels come presterilized and prepacked with matrix ready-to-use. “We have also developed our own process controller for the system, says Havelange.

    The company’s mixing technology relies on a centrifugal pump driven by a magnetic motor. The falling film allows efficient gas transfer for oxygenation. A 25 L fixed-bed iCELLis bioreactor “is equivalent to a 20–30-fold increased volume in a traditional stirred tank reactor, or a 500–800 L working volume,” says Havelange.

    Artelis has a co-development agreement with Cardio3 BioSciences, a company developing regenerative therapies for treating heart failure, to build a fully enclosed GMP system for producing autologous mesenchymal stem cells.

    “We believe there is a strong need for process technologies and bioprocess intensification in stem cell production,” adds Havelange.

    Pierre Guerin Technologies’ single-use Nucleo bioreactors and fermentors can accommodate disposable bags ranging in scale from 25 L to 500 L working volume, with a 1,000 L capacity bioreactor due on the market during the third quarter of this year and a 1,000 L scale fermentor expected toward the end of 2009 or in early 2010. The systems are compatible with industry-standard PLC controllers and supervisory platforms, according to Doro Felezeu, director of marketing and business development at Pierre Guerin.

    Felezeu anticipates growing interest in the production of high density cell cultures, or “cell concentrates,” for use in feeding bioreactors and for cell therapy applications. “Imagine the advantages if you could get the same results with a 100 L bioreactor versus a 1,000 L bioreactor,” says Felezeu. Very high density cell growth would require optimal process conditions and new types of sensors to allow for accurate control of a broader range of parameters.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?